We've found
17,819
archived clinical trials in
Brain Cancer
We've found
17,819
archived clinical trials in
Brain Cancer
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Updated: 12/31/1969
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Updated: 12/31/1969
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Updated: 12/31/1969
Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials